Xolair 75 MG/0.5 ML syringe 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCRR4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,741
Award facts
- Contract value 100% obligated
- $19,740.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19,740.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 75 mg/0.5 mL syringes. The contract, which carries no set-aside designation, is scheduled for completion by January 15, 2026, and represents a discrete purchase order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency. This delivery order falls within the scope of the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy established to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has been a registered federal contractor since 2001 and has demonstrated substantial contracting activity with the Defense Logistics Agency's Medical Supply Chain division, supplying an extensive portfolio of branded and generic pharmaceuticals, biologics, vaccines, and medical consumables. The vendor's prime contract under PPV-G GEN V, valued at $499,999,999 with completion anticipated in December 2036, positions the company as a critical regional pharmaceutical supplier supporting military healthcare operations. The current delivery order for Xolair, a biologic immunosuppressant, reflects the company's ongoing role in fulfilling specialized pharmaceutical requirements across the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCRR4?
SPE2DR26FCRR4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 23, 2025.
How much is contract SPE2DR26FCRR4 worth?
The government has obligated $19,741 on SPE2DR26FCRR4.
Is contract SPE2DR26FCRR4 an order under another contract?
Yes. SPE2DR26FCRR4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRR4 competed?
The extent of competition for SPE2DR26FCRR4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award